<DOC>
	<DOCNO>NCT00020566</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . It yet know combination chemotherapy effective without radiation therapy and/or surgery treat Ewing 's sarcoma . PURPOSE : This randomized phase III trial study different combination chemotherapy regimens see well work give without peripheral stem cell transplantation , radiation therapy , and/or surgery treat patient Ewing 's sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Peripheral Stem Cell Transplantation , Radiation Therapy , and/or Surgery Treating Patients With Ewing 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free overall survival patient tumor Ewing 's family treat standard induction chemotherapy comprise vincristine , dactinomycin , ifosfamide etoposide ( VIDE ) follow consolidation chemotherapy comprise vincristine , dactinomycin , ifosfamide versus high-dose busulfan melphalan ( Bu-Mel ) follow autologous peripheral blood stem cell ( PBSC ) transplantation without radiotherapy and/or surgery . Secondary - Determine prognostic significance EWS-Flil transcript patient . - Determine frequency prognostic value minimal disease bone marrow PBSC , determine presence absence EWS-Flil transcript , patient . - Determine feasibility toxicity VIDE induction chemotherapy patient . - Determine response patient VIDE induction chemotherapy . - Determine feasibility toxicity VAI consolodation chemotherapy patient . - Determine feasibility toxicity Bu-Mel consolodation chemotherapy patient . - Determine event-free survival overall survival patient treat regimen prognostic group analysis . OUTLINE : This randomize , multicenter study . Patients stratify accord age local treatment primary tumor ( yes v ) . Patients receive induction chemotherapy comprise vincristine IV day 1 ifosfamide IV 3 hour , doxorubicin IV 4 hour , etoposide IV 1 hour day 1-3 ( VIDE ) . Treatment repeat every 21 day 4 course absence unacceptable toxicity . Peripheral blood stem cell ( PBSC ) collect course 3 and/or 4 . Patients evaluate course 4 . Patients need early radiotherapy due axial tumor patient require radiotherapy brain and/or spinal cord ( time study ) assign group 1 . Patients need early radiotherapy assign group 2 . - Group 1 : Patients receive 2 additional course VIDE induction chemotherapy ( course 5 6 ) . Patients require radiotherapy axial tumor also undergo concurrent radiotherapy 5 day week . Some patient may undergo surgical resection tumor . All patient receive vincristine IV day 1 dactinomycin IV ifosfamide IV 3 hour day 1 2 ( VAI ) . Treatment repeat every 21 day 8 course ( course 7-14 ) . Patients require radiotherapy brain and/or spinal cord also undergo concurrent radiotherapy . - Group 2 : Patients undergo 2 additional course VIDE induction chemotherapy ( course 5 6 ) . Some patient may undergo surgical resection tumor . All patient receive VAI chemotherapy group 1 1 course . Patients randomize 1 2 consolidation therapy arm . - Arm I : Patients receive 7 additional course VAI chemotherapy ( course 8-14 ) . Patients unresectable , partially resect , inadequately resected disease undergo concurrent whole-lung radiotherapy 6-12 day . - Arm II : Patients receive high-dose chemotherapy comprise oral busulfan every 6 hour day -6 -3 melphalan IV 30 minute day -2 . Patients receive autologous PBSC IV day 0 . Patients unresectable , partially resect , inadequately resected disease undergo concurrent radiotherapy 5 day week least 5 week . Patients follow every 3 month 4 year , every 6 month 1 year , periodically thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 1,200 patient accrue study within approximately 7 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm tumor Ewing 's family bone soft tissue Ewing 's sarcoma Peripheral primitive neuroectodermal tumor Disease meet one follow criterion : Resectable localized disease ( tumor volume le 200 mL ) Localized disease previously resect diagnosis Unresectable disease ( least 200 mL tumor volume ) radiotherapy local control delay Localized disease early radiotherapy require Pulmonary and/or pleural metastasis Extrapulmonary/pleural metastasis ( skeleton , bone marrow , lymph node ) No 45 day since definitive biopsy PATIENT CHARACTERISTICS : Age : Under 50 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Renal function normal Glomerular filtration rate least 60 mL/min Cardiovascular : Normal cardiac function Fractional shortening least 29 % Ejection fraction least 40 % Other : No medical , psychiatric , social condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>